Dr. Mullin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
30 Buxton Farm Rd
Ste 230
Stamford, CT 06905Phone+1 203-914-1900Fax+1 203-914-1903
Education & Training
- New York Presbyterian Hospital (Columbia Campus)Residency, Neurology, 2008 - 2011
- Westchester Medical CenterInternship, Internal Medicine, 2007 - 2008
- New York University School of MedicineClass of 2007
Certifications & Licensure
- CT State Medical License 2018 - 2025
- NY State Medical License 2008 - 2025
- American Board of Psychiatry and Neurology Neurology
- United Council for Neurologic SubspecialtiesHeadache Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Publications & Presentations
PubMed
- 48 citationsPotential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.Kathleen Mullin, David Kudrow, Robert Croop, Meghan Lovegren, Charles M. Conway
Neurology. 2020-05-19 - 14 citationsPatient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.Andrew M. Blumenfeld, Atul T. Patel, Ira M. Turner, Kathleen B Mullin, Aubrey Manack Adams
Journal of Primary Care & Community Health. 2020-09-27 - 6 citationsEducation and decision making at the time of triptan prescribing: patient expectations vs actual practice.Paul Mathew, Jelena M. Pavlovic, Alyssa Lettich, Rebecca Erwin Wells, Carrie E. Robertson
Headache. 2014-04-01
Press Mentions
- Zavzpret (Zavegepant) Migraine Nasal Spray from Pfizer Gets FDA NodMarch 14th, 2023
- Migraine Nasal Spray from Pfizer Snags FDA Approval for Expected Summer LaunchMarch 11th, 2023
- FDA Approves a New Nasal Spray to Treat MigrainesMarch 10th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: